Identification of Potential Drug Targets and Biomarkers for Neurodegenerative Disorders

Target Name: CTNNBIP1

NCBI ID: G56998

CTNNBIP1

Identification of Potential Drug Targets and Biomarkers for Neurodegenerative Disorders

CTNNBIP1 (Cytokine-Induced Neurogenesis Inhibitor), also known as OTTHUMP00000001722, is a protein that is expressed in various tissues of the body, including the brain. It has been identified as a potential drug target for the treatment of various neurological disorders, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders.

The protein CTNNBIP1 is composed of 254 amino acids and has a molecular weight of 31 kDa. It is a cytokine-induced neurogenesis inhibitor, which means that it works by inhibiting the production of progenitor cells that give rise to new neurons in the brain. This is a key mechanism in the development and progression of neurodegenerative disorders.

The search for potential drug targets for neurodegenerative disorders has led to the identification of numerous protein validated as potential therapeutic targets. CTNNBIP1 is one of these proteins, which has been shown to be involved in the development and progression of various neurological disorders.

One of the key features of CTNNBIP1 is its ability to induce neurogenesis in the adult brain. This is an important finding because it suggests that the protein may have a role in the repair and regeneration of damaged brain tissue. This is a promising sign because it suggests that the protein may be a useful target for the treatment of neurodegenerative disorders.

Another important feature of CTNNBIP1 is its ability to modulate the activity of other proteins involved in the development and progression of neurodegenerative disorders. This is done through the use of various post-translational modifications, which are changes in the structure of the protein that occur after it has been synthesized.

The post-translational modifications of CTNNBIP1 have been shown to play a role in its ability to modulate the activity of other proteins. For example, studies have shown that the protein can interact with the protein PDGF-BB, which is involved in the development and progression of various cancers, including breast cancer. This interaction suggests that CTNNBIP1 may be a useful target for the treatment of cancer.

In addition to its potential role in the development and progression of neurodegenerative disorders and cancer, CTNNBIP1 is also of interest as a potential biomarker. This is because the protein is expressed in various tissues of the body, including the brain, and can be used as a marker for the diagnosis and monitoring of neurodegenerative disorders and cancer.

The identification of potential drug targets and biomarkers for neurodegenerative disorders is an important step in the development of new treatments for these conditions. CTNNBIP1 is one of these proteins, which has been shown to have a role in the development and progression of various neurological disorders. Further research is needed to determine its full potential as a drug target and biomarker.

Protein Name: Catenin Beta Interacting Protein 1

Functions: Prevents the interaction between CTNNB1 and TCF family members, and acts as negative regulator of the Wnt signaling pathway

The "CTNNBIP1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTNNBIP1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets